Dr. Knopman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. David Knopman is a neurologist at the Mayo Clinic, Rochester. He received his medical degree from University of Minnesota Medical School and has been in practice 42 years. He specializes in neurodegenerative and dementia & geriatrics.
Education & Training
- University of MinnesotaResidency, Neurology, 1976 - 1979
- Hennepin HealthcareInternship, Transitional Year, 1975 - 1976
- University of Minnesota Medical SchoolClass of 1975
- Dartmouth CollegeA.B., Biology, 1972
Certifications & Licensure
- MN State Medical License 1978 - 2025
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Phi Beta Kappa Honor Society 1972
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Publications & Presentations
PubMed
- Impact of alcohol use disorder on cognition in correlation with aging: a community-based retrospective cohort study.Hesham Essa, Hossam M Ali, Paul H Min, Dina N Ali, Val Lowe
Alcohol and Alcoholism. 2024-11-18 - Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers.Val J Lowe, Carly T Mester, Emily S Lundt, Jeyeon Lee, Sujala Ghatamaneni
Alzheimer's & Dementia. 2024-11-01 - A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.Howard H Feldman, Jeffrey L Cummings, Adam L Boxer, Adam M Staffaroni, David S Knopman
Alzheimer's & Dementia. 2024-11-01
Journal Articles
- Association of Initial Β-amyloid Levels with Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive ImpairmentDavid S Knopman, Bradley F Boeve, Ronald C Petersen, Clifford R Jack, JAMA Neurology
- Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated with MAPT, GRN, and C9orf72 Pathogenic VariantsNupur Ghoshal, Neill R Graff-Radford, David S Knopman, Zbigniew K Wszolek, Joel H Kramer, Bradley F Boeve, Howard J Rosen, JAMA Network Open
- Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without DementiaMary M Machulda, Ronald C Petersen, David S Knopman, Yonas E Geda, Val J Lowe, Journal of the American Geriatrics Society
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Tdp-43 influences cognition, memory loss and hippocampal atrophy in Alzheimer's disease.Josephs K, Whitwell J, Weigand S, Murray M, Tosakulwong N, Liesinger A, Petrucelli L, Knopman D, Boeve B, Ivnik R, Smith G, Jack C, Parisi J, Petersen R, Dickson D, J Neuropathol Exp Neurol, 6/1/2014
- Antemortem characterization of a kindred carrying the non-coding GGGGCC hexanucleotide repeat expansion in C9ORF72.Adeli A, Boeve B, DeJesus-Hernandez M, Baker M, Rutherford N, Knopman D, Ivnik R, Fields J, Petersen R, Rademakers R, Neurology, 4/1/2012
- Characterization of the neuropsychiatric features associated with mutations in C9ORF72'MAPT and PGRN.Adeli A, Geda Y, Boeve B, Graff-Radford N, DeJesus-Hernandez M, Knopman D, Josephs K, Pedraza O, Rush B, Fields J, Rutherford N, Baker M, Smith G, Ivnik R, Pankratz V,..., Neurology, 4/1/2012
- Join now to see all
Lectures
- Alzheimers DiseaseCuritiba, Brazil - 4/1/2004
- Symptoms of DementiaUniversity of Colorado - 3/1/2004
- 7th International Conference on Alzheimer's Disease7/1/2000
- Join now to see all
Press Mentions
- Your Brain in Your 40sNovember 23rd, 2024
- Hearing Loss Tied to Cognitive Decline, Even with Hearing Aid UseOctober 8th, 2024
- Alzheimer’s Drugs Are Arriving, but They Won’t Be Risk FreeMay 23rd, 2023
- Join now to see all
Grant Support
- Validating The New Criteria For Preclinical Alzheimer'S DiseaseNational Institute On Aging2012
- Frontotemporal Degeneration: A Basis For Clinical TrialsNational Institute On Aging2004–2006
- Frontotemporal Degeneration: A Basis For Clinical TrialsNational Institute On Aging2003
- Epidemiology Of Alzheimer Disease In A Total PopulationNational Institute On Aging1992–1994
- Scientific Evaluation And PlanningNational Institute Of Mental Health1991–1994
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: